ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials

Rao, Naren P and Remington, Gary (2013) Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. In: Expert Opinion on Investigational Drugs, 22 (7). pp. 881-894.

Full text not available from this repository. (Request a copy)
Official URL: http://dx.doi.org/10.1517/13543784.2013.795945

Abstract

Introduction: For over half a century now, the dopamine hypothesis has provided the most widely accepted heuristic model linking pathophysiology and treatment in schizophrenia. Despite dopaminergic drugs being available for six decades, this system continues to represent a key target in schizophrenia drug discovery. The present article reviews the scientific rationale for dopaminergic medications historically and the shift in our thinking since, which is clearly reflected in the investigational drugs detailed. Areas covered: We searched for investigational drugs using the key words `dopamine,' `schizophrenia,' and `Phase II' in American and European clinical trial registers (clinicaltrials. gov; clinicaltrialsregister.eu), published articles using National Library of Medicine's PubMed database, and supplemented results with a manual search of cross-references and conference abstracts. We provide a brief description of drugs targeting dopamine synthesis, release or metabolism, and receptors (agonists/partial agonists/antagonists). Expert opinion: There are prominent shifts in how we presently conceptualize schizophrenia and its treatment. Current efforts are not as much focused on developing better antipsychotics but, instead, on treatments that can improve other symptom domains, in particular cognitive and negative. This new era in the pharmacotherapy of schizophrenia moves us away from the older `magic bullet' approach toward a strategy fostering polypharmacy and a more individualized approach shaped by the individual's specific symptom profile.

Item Type: Journal Article
Additional Information: Copyright of this article belongs to Informa Healthcare.
Keywords: Dopamine Receptor; Dopaminergic; Phase II; Schizophrenia
Department/Centre: Division of Interdisciplinary Research > Centre for Nano Science and Engineering
Depositing User: Francis Jayakanth
Date Deposited: 19 Sep 2013 17:32
Last Modified: 19 Sep 2013 17:32
URI: http://eprints.iisc.ac.in/id/eprint/47212

Actions (login required)

View Item View Item